Evidence underlying the American Heart Association/American College of Cardiology (AHA/ACC) guidelines for peripheral vascular intervention (PVI) is often of poor quality, a new analysis has found.
Visit WebsiteDespite advancements in STEMI care and protocol in recent years, discrepancies in treatment and patient presentation related to socioeconomic status and insurance remain, according to two new studies.
Visit WebsiteVarious imaging technologies are relevant to the diagnosis, treatment, and follow-up of patients with nonvalvular structural heart disease. But until now, clinicians needed to consult separate documents for guidance on which tool to choose. New appropriate use criteria (AUC) released today aim to streamline that decision-making by instead focusing on disease states as a whole, rather than on individual modalities.
Visit WebsiteLong-term rates of mortality and recurrence following an index Takotsubo syndrome event are not negligible, and older age, physical stress, and atypical ballooning at presentation are each associated with worse prognosis, according to a new systematic review.
Visit WebsiteThe Hospital Readmissions Reduction Program (HRRP), enacted by the 2010 Affordable Care Act, appears to have led to an increase in deaths within 30 days of discharge…..leading researchers to conclude that more investigation is needed into the possibility that the program has had unintended negative consequences.
Visit WebsiteKey opinion leaders seem obliged to come up with “excuses” to explain disappointing trial results, Darrel Francis MD (Imperial College London, England) says.
Visit WebsiteCasting more light on the relationship between procedural volume and in-hospital adverse events, a new study shows that individual operator experience with transcatheter aortic valve replacement is important for achieving the best possible clinical outcomes.
Visit WebsiteDUBAI, United Arab Emirates—E-cigarettes are being marketed as safer alternatives to traditional cigarettes and as aids to help people quit smoking, but there is some evidence that they could be having adverse effects on the cardiovascular system, a new review shows.
Visit WebsiteIn a disturbing new study, use of paclitaxel-coated balloons and stents in peripheral artery disease appeared to heighten the risk of all-cause death in patients with femoropopliteal artery disease, calling into question what has been the mainstay therapy in this hard-to-treat group.
Visit WebsitePatients with prior MI and elevated high-sensitivity C-reactive protein (hsCRP) see a dose-dependent reduction in heart-failure hospitalization while taking the anti-inflammatory drug canakinumab (Novartis), researchers reported Sunday at the American Heart Association (AHA) 2018 Scientific Sessions in Chicago, IL. The difference between canakinumab and placebo was only significant, however, among patients who achieved on-treatment hsCRP concentrations < 2 mg/L.
Visit Website